Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Mol Sci
Main Authors: Carofiglio, Francesca, Lopalco, Antonio, Lopedota, Angela, Cutrignelli, Annalisa, Nicolotti, Orazio, Denora, Nunzio, Stefanachi, Angela, Leonetti, Francesco
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2020
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/
https://ncbi.nlm.nih.gov/pubmed/32586039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker